Alzheimer's Disease, Late Onset Clinical Trial
— FIT-ADOfficial title:
Aerobic Exercise in Alzheimer's Disease: Cognition and Hippocampal Volume Effects
| Verified date | February 2022 |
| Source | University of Minnesota |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This randomized controlled trial (RCT) will investigate the effects of a 6-month, individualized, moderate-intensity cycling intervention on cognition and hippocampal volume in AD with three aims: - Determine the immediate effect of the cycling intervention on cognition in AD. - Examine if the cycling intervention slows cognitive decline in AD from baseline to 12 months. - Assess the effect of aerobic exercise on hippocampal volume in AD over 12 months using MRI. The investigators will randomize 90 participants to the 6-month cycling or stretching/range of motion exercise (20-50-minute, 3 times a week). Participants will then be followed for another 6 months. Cognition will be assessed at baseline, 3, 6, 9, and 12 months and hippocampal volume will be measured using magnetic resonance imaging (MRI) at baseline, 6, and 12 months.
| Status | Completed |
| Enrollment | 96 |
| Est. completion date | April 30, 2021 |
| Est. primary completion date | April 30, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 66 Years and older |
| Eligibility | Inclusion Criteria: - Diagnosis of probable or possible Alzheimer's disease (AD); - 15= Mini-Mental State Examination (MMSE) score =26; - Clinical Dementia Rating score 0.5-2; - Community-dwelling, e.g., homes and assisted living; - Age 66 years and older; - English-speaking; - Verified exercise safety by the primary care providers and the cardiologists if subjects have significant cardiac history; - Stable on AD drugs >1 month if AD drugs are prescribed. Exclusion Criteria: - Resting heart rate (HR) =50 or =100 beats/min; - Neurological disorders in the past 5 years; - Psychiatric disorders in the past 5 years; - Alcohol or chemical dependency in the past 5 years; - Contraindications to exercise; - New symptoms or diseases that have not been evaluated by a health care provider, e.g., hip fracture, ongoing and unplanned weight loss, severe shortness of breath, deep vein thrombosis, hernia, unhealed sores, joint swelling, pain or trouble walking; - Cardiac ischemia or serious arrhythmia on the electrocardiograph during the screening exercise test. |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Minnesota | Minneapolis | Minnesota |
| Lead Sponsor | Collaborator |
|---|---|
| University of Minnesota | Mayo Clinic, National Institute on Aging (NIA), University of St Thomas |
United States,
Yu F, Bronas UG, Konety S, Nelson NW, Dysken M, Jack C Jr, Wyman JF, Vock D, Smith G. Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial). Trials. 2014 Oct 11;15:394. doi: 10.1186/1745-6215-15-394. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in cognition from baseline to 6 months as measured by the Alzheimer's Disease Assessment Scale - Cognitive Subscale | This outcome measure will be given to all study participants. | Baseline, 3 months, 6 months, 9 months, and 12 months | |
| Secondary | Change in hippocampal volume as measured by Magnetic Resonance Imaging (MRI) | Only participants who qualified to undergo MRI will be assessed for hippocampal volume. | Baseline, 6 months, and 12 months |